Overview
BNGO market data
Price History
BNGO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.85 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -110.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.00 – $5.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $13.8M · P/B 0.35 · P/S 0.48.
Company News
Bionano Genomics Q2 EPS $(0.64) Beats $(0.69) Estimate, Sales $8.171M Beat $7.476M EstimateBenzinga · Aug 10, 2026, 8:50 PM
Bionano Genomics Q2 Sales $8.171M Beat $7.476M EstimateBenzinga · Aug 10, 2026, 8:12 PM
Bionano Genomics Raises FY2026 Sales Guidance from $30.000M-$33.000M to $31.000M-$33.000M vs $32.137M EstBenzinga · Aug 10, 2026, 8:07 PM
Bionano Genomics Sees Q3 Sales $8.200M-$8.600M vs $8.575M EstBenzinga · Aug 10, 2026, 8:07 PM
8-K filing — Bionano Genomics, Inc. (BNGO)SEC EDGAR · Jun 24, 2026, 12:30 PM
Bionano Genomics Announces Publication Of Largest OGM Study Of T-Cell Acute Lymphoblastic Leukemia With 97.8% Detection RateBenzinga · May 26, 2026, 12:03 PM